@article{6e4e305780c1423cb20234edc287f76a,
title = "The interface between depression and dementia: Where are we with this important frontier?",
author = "Lyketsos, {Constantine G.}",
note = "Funding Information: Dr. Lyketsos has received grant support from NIMH, NIA, Associated Jewish Federation of Baltimore, Weinberg Foundation, Forest, Glaxo-Smith-Kline, Eisai, Pfizer, Astra-Zeneca, Lilly, Ortho-McNeil, Bristol-Myers, and Novartis. He has served as a consultant or advisor for Astra-Zeneca, Glaxo-Smith Kline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, and Genentech. He has been paid a speaking honorarium or travel support from Pfizer, Forest, Glaxo-Smith Kline, and Health Monitor. Funding Information: This editorial was supported in part by grant 5 PO1 AGO5146 to the Johns Hopkins Alzheimer's Disease Research Center where Dr. Lyketsos serves as Clinical Core Leader. ",
year = "2010",
month = feb,
doi = "10.1097/JGP.0b013e3181c79641",
language = "English (US)",
volume = "18",
pages = "95--97",
journal = "American Journal of Geriatric Psychiatry",
issn = "1064-7481",
publisher = "Lippincott Williams and Wilkins",
number = "2",
}